Platform & Pipeline
Platform:
Exosome Therapeutic Platform: Exosomes derived from Mesenchymal Stromal Cells (MSCs) are optimized through specific priming methods to enhance yield and therapeutic efficacy for different indications. We have developed a proprietary manufacturing platform to achieve this.
Vaginal Drug Delivery Platform: Vaginal suppositories made from clinically proven, biocompatible, and biodegradable materials, featuring high drug-loading capacity and sustained-release characteristics. Based on the unique vaginal environment, we have developed a proprietary vaginal drug delivery suppository that ensures both safety and high efficiency.
Pipeline:
Vaginal Rejuvenation Kit:
Our initial focus addresses one of the most overlooked and underserved conditions in women’s health—Genitourinary Syndrome of Menopause (GSM), also known as vaginal atrophy. Our first innovation, the Vaginal Rejuvenation Kit, is a non-hormonal, disease-modifying, regenerative therapy designed to restore atrophic vaginal tissue to a normal, healthy state. This breakthrough solution combines proprietary exosome therapy derived from mesenchymal stromal cells with a novel vaginal delivery technology. Convenient, safe, and effective, this therapy represents a transformative advancement in women’s health—and a once-in-a-generation opportunity to improve the lives of millions of women worldwide.
